ELBLANDKLINIKEN Stiftung & Co. KG

At ELBLANDKLINIKEN Stiftung & Co. KG in Riesa, clinical research in hematology focuses on difficult blood cancers, especially acute myeloid leukemia and high-risk myelodysplastic neoplasia. The studies are designed to assess whether new treatment approaches can improve early response and overall disease control for patients with aggressive hematologic malignancies.

• Evaluating a new therapy approach for newly diagnosed acute myeloid leukemia
• Studying treatment effectiveness in high-risk myelodysplastic neoplasia
• Measuring best remission outcomes during induction treatment

These trials reflect a strong interest in improving outcomes for patients who may need intensive care and, in some cases, later stem cell transplantation.

The site also conducts research in respiratory oncology, with a focus on metastatic TTF-1 negative lung adenocarcinoma. The clinical trial work compares established treatment combinations to see which option offers better survival and disease control for patients with advanced lung cancer.

• Comparing two treatment strategies for metastatic lung adenocarcinoma
• Assessing survival outcomes in advanced respiratory tract cancer
• Supporting treatment selection in difficult-to-treat TTF-1 negative disease

This research aims to help identify more effective therapy options for patients with limited treatment choices, while contributing to better understanding of advanced thoracic malignancies.